Both well-established and small, clinical-stage pharma companies are investing heavily to be able to someday compete with ...

Top executives ignored warnings that the company was not sufficiently prepared for the launch of its weight-loss drug Wegovy, ...

Novo Nordisk said it will stop selling Wegovy on Hims & Hers, claiming the telehealth company sold knockoff versions of the ...

Novo Nordisk said Monday it will end its collaboration with Hims & Hers that offered the weight loss medication Wegovy for ...

Novo Nordisk A/S and Eli Lilly & Co, the pharmaceutical giants dominating the global obesity drug market, now face their ...

Novo Nordisk's U.S.-listed shares fell close to 6% Monday after the drugmaker revealed the latest results for a new ...

Eli Lilly and Novo Nordisk, which already have approved GLP-1 weight loss drugs that are raking in billions of revenues, have ...

Amycretin helped patients lose over 24% of their weight, compared with an average of about 17% for Wegovy.

Novo Nordisk A/S is hunting for more early-stage deals to pad its pipeline of next-generation obesity drugs, as the drugmaker ...

Novo Nordisk's CagriSema achieved significant weight loss in phase 3 trials, though safety concerns may limit its edge over ...

Walmart has agreed to pay $10 million to settle a U.S. Federal Trade Commission civil lawsuit accusing the world's largest ...

Shares in Denmark's pharmaceutical giant Novo Nordisk (NYSE: NVO) were lower by 4% as of 11 a.m. ET today. The move comes as ...